p.72 抽出テキスト
34. Sgreccia D, Manicardi M, Malavasi VL, Vitolo M, Valenti AC, Proietti M, et al. Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic review and meta-analysis of 81,462 patients. J Clin Med 2021;10:3979. https://doi.org/ 10.3390/jcm10173979 35. Holmes DN, Piccini JP, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, et al. Defining clinically important difference in the atrial fibrillation effect on quality-of-life score. Circ Cardiovasc Qual Outcomes 2019;12:e005358. https://doi.org/10.1161/ CIRCOUTCOMES.118.005358 36. Jones J, Stanbury M, Haynes S, Bunting KV, Lobban T, Camm AJ, et al. Importance and assessment of quality of life in symptomatic permanent atrial fibrillation: patient focus groups from the RATE-AF trial. Cardiology 2020;145:666–75. https://doi.org/10.1159/ 000511048 37. Abu HO, Wang W, Otabil EM, Saczynski JS, Mehawej J, Mishra A, et al. Perception of atrial fibrillation symptoms: impact on quality of life and treatment in older adults. J Am Geriatr Soc 2022;70:2805–17. https://doi.org/10.1111/jgs.17954 38. Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC; RACE Investigators. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm 2014;11:939–45. https://doi.org/10.1016/j.hrthm.2014.03.016 39. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018;39:2987–96. https://doi.org/10.1093/eurheartj/ehx739 40. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm 2014;11:1543–50. https://doi.org/10.1016/j.hrthm.2014.06.007 41. Kloosterman M, Crijns H, Mulder BA, Groenveld HF, Van Veldhuisen DJ, Rienstra M, et al. Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. Europace 2020;22: 1619–27. https://doi.org/10.1093/europace/euz300 42. Park YJ, Park JW, Yu HT, Kim TH, Uhm JS, Joung B, et al. Sex difference in atrial fibrillation recurrence after catheter ablation and antiarrhythmic drugs. Heart 2023;109: 519–26. https://doi.org/10.1136/heartjnl-2021-320601 43. Kupper N, van den Broek KC, Widdershoven J, Denollet J. Subjectively reported symptoms in patients with persistent atrial fibrillation and emotional distress. Front Psychol 2013;4:192. https://doi.org/10.3389/fpsyg.2013.00192 44. Schnabel RB, Michal M, Wilde S, Wiltink J, Wild PS, Sinning CR, et al. Depression in atrial fibrillation in the general population. PLoS One 2013;8:e79109. https://doi.org/ 10.1371/journal.pone.0079109 45. Gleason KT, Dennison Himmelfarb CR, Ford DE, Lehmann H, Samuel L, Han HR, et al. Association of sex, age and education level with patient reported outcomes in atrial fibrillation. BMC Cardiovasc Disord 2019;19:85. https://doi.org/10.1186/s12872-019- 1059-6 46. Schnabel RB, Pecen L, Rzayeva N, Lucerna M, Purmah Y, Ojeda FM, et al. Symptom burden of atrial fibrillation and its relation to interventions and outcome in Europe. J Am Heart Assoc 2018;7:e007559. https://doi.org/10.1161/JAHA.117.007559 47. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014;16:965–72. https://doi. org/10.1093/europace/eut395 48. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 2020;324:2497–508. https://doi.org/10. 1001/jama.2020.23138 49. Kotecha D, Ahmed A, Calvert M, Lencioni M, Terwee CB, Lane DA. Patient-reported outcomes for quality of life assessment in atrial fibrillation: a systematic review of measurement properties. PLoS One 2016;11:e0165790. https://doi.org/10.1371/ journal.pone.0165790 50. Mantovan R, Macle L, De Martino G, Chen J, Morillo CA, Novak P, et al. Relationship of quality of life with procedural success of atrial fibrillation (AF) ablation and postablation AF burden: substudy of the STAR AF randomized trial. Can J Cardiol 2013;29:1211–7. https://doi.org/10.1016/j.cjca.2013.06.006 51. Samuel M, Khairy P, Champagne J, Deyell MW, Macle L, Leong-Sit P, et al. Association of atrial fibrillation burden with health-related quality of life after atrial fibrillation ablation: substudy of the cryoballoon vs contact-force atrial fibrillation ablation (CIRCA-DOSE) randomized clinical trial. JAMA Cardiol 2021;6:1324–8. https://doi. org/10.1001/jamacardio.2021.3063 52. Sandhu RK, Smigorowsky M, Lockwood E, Savu A, Kaul P, McAlister FA. Impact of electrical cardioversion on quality of life for the treatment of atrial fibrillation. Can J Cardiol 2017;33:450–5. https://doi.org/10.1016/j.cjca.2016.11.013 53. Terricabras M, Mantovan R, Jiang CY, Betts TR, Chen J, Deisenhofer I, et al. Association between quality of life and procedural outcome after catheter ablation for atrial fibrillation: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2020;3: e2025473. https://doi.org/10.1001/jamanetworkopen.2020.25473 54. Zenger B, Zhang M, Lyons A, Bunch TJ, Fang JC, Freedman RA, et al. Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: results from the Utah mEVAL AF program. J Cardiovasc Electrophysiol 2020;31:3187–95. https://doi.org/10.1111/jce.14795 55. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace 2021;23:494–5. https://doi.org/10.1093/europace/euaa253 56. Kvist LM, Vinter N, Urbonaviciene G, Lindholt JS, Diederichsen ACP, Frost L. Diagnostic accuracies of screening for atrial fibrillation by cardiac nurses versus radiographers. Open Heart 2019;6:e000942. https://doi.org/10.1136/openhrt-2018-000942 57. Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013;34:1475–80. https://doi.org/10.1093/eurheartj/ eht024 58. Berg DD, Ruff CT, Morrow DA. Biomarkers for risk assessment in atrial fibrillation. Clin Chem 2021;67:87–95. https://doi.org/10.1093/clinchem/hvaa298 59. Tops LF, Schalij MJ, Bax JJ. Imaging and atrial fibrillation: the role of multimodality imaging in patient evaluation and management of atrial fibrillation. Eur Heart J 2010;31: 542–51. https://doi.org/10.1093/eurheartj/ehq005 60. Obeng-Gyimah E, Nazarian S. Advancements in imaging for atrial fibrillation ablation: is there a potential to improve procedural outcomes? J Innov Card Rhythm Manag 2020; 11:4172–8. https://doi.org/10.19102/icrm.2020.110701 61. Romero J, Husain SA, Kelesidis I, Sanz J, Medina HM, Garcia MJ. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging 2013;6:185–94. https://doi.org/10.1161/ CIRCIMAGING.112.000153 62. Bisbal F, Benito E, Teis A, Alarcón F, Sarrias A, Caixal G, et al. Magnetic resonance imaging-guided fibrosis ablation for the treatment of atrial fibrillation: the ALICIA trial. Circ Arrhythm Electrophysiol 2020;13:e008707. https://doi.org/10.1161/CIRCEP.120. 008707 63. Khurram IM, Habibi M, Gucuk Ipek E, Chrispin J, Yang E, Fukumoto K, et al. Left atrial LGE and arrhythmia recurrence following pulmonary vein isolation for paroxysmal and persistent AF. JACC Cardiovasc Imaging 2016;9:142–8. https://doi.org/10.1016/j.jcmg. 2015.10.015 64. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 2014;311:498–506. https:// doi.org/10.1001/jama.2014.3 65. Roney CH, Sillett C, Whitaker J, Lemus JAS, Sim I, Kotadia I, et al. Applications of multimodality imaging for left atrial catheter ablation. Eur Heart J Cardiovasc Imaging 2021; 23:31–41. https://doi.org/10.1093/ehjci/jeab205 66. Potter A, Augustine DX, Ingram TE. Referring for echocardiography: when not to test. Br J Gen Pract 2021;71:333–4. https://doi.org/10.3399/bjgp21X716441 67. Troughton RW, Asher CR, Klein AL. The role of echocardiography in atrial fibrillation and cardioversion. Heart 2003;89:1447–54. https://doi.org/10.1136/heart.89.12.1447 68. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 2016;354:i4482. https://doi.org/10.1136/bmj.i4482 69. Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol 2017;24:1555–66. https://doi. org/10.1177/2047487317715769 70. Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation. PLoS One 2018; 13:e0191592. https://doi.org/10.1371/journal.pone.0191592 71. Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016;37:2882–9. https://doi.org/10.1093/eurheartj/ ehw233 72. Hornestam B, Adiels M, Wai Giang K, Hansson PO, Björck L, Rosengren A. Atrial fibrillation and risk of venous thromboembolism: a Swedish nationwide registry study. Europace 2021;23:1913–21. https://doi.org/10.1093/europace/euab180 73. Lutsey PL, Norby FL, Alonso A, Cushman M, Chen LY, Michos ED, et al. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the atherosclerosis risk in communities study. J Thromb Haemost 2018;16:670–9. https://doi.org/10. 1111/jth.13974 74. Koh YH, Lew LZW, Franke KB, Elliott AD, Lau DH, Thiyagarajah A, et al. Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals. Europace 2022;24:1229–39. https://doi.org/10.1093/europace/ euac003 75. Papanastasiou CA, Theochari CA, Zareifopoulos N, Arfaras-Melainis A, Giannakoulas G, Karamitsos TD, et al. Atrial fibrillation is associated with cognitive impairment, allcause dementia, vascular dementia, and Alzheimer’s disease: a systematic review and meta-analysis. J Gen Intern Med 2021;36:3122–35. https://doi.org/10.1007/s11606- 021-06954-8 76. Giannone ME, Filippini T, Whelton PK, Chiari A, Vitolo M, Boriani G, et al. Atrial fibrillation and the risk of early-onset dementia: a systematic review and meta-analysis. J Am Heart Assoc 2022;11:e025653. https://doi.org/10.1161/JAHA.122.025653 ESC Guidelines 3385 Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026